We recently published a list of Billionaire George Soros Stock Portfolio: Top 10 Stock Picks. In this article, we are going ...

Jim Lebenthal, chief equity strategist at Cerity Partners, joins CNBC's 'Halftime Report' to explain why he's buying the ...

Hagens Berman has opened an investigation into the allegations and urges investors in AstraZeneca American Depositary Shares ...

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

AstraZeneca has been taking a wider role in Vietnam’s healthcare sector to help expand access to quality healthcare.

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

Oppenheimer initiated coverage of Compugen (CGEN) with an Outperform rating and $4 price target. With a sole oncology focus, Compugen is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...